x

Consumer Guides

Government  Guides

Consumer News

Consumer Guide
Index

Consumer Guides
Home

Submit Government Guide

Submit Article
Consumer News Articles on
Products and Services

Copywriting Services

Auctions

Auction Houses

Internet Auctions

Adoption

Adoption Professionals

Adoption Record Access

Single Parent Adoption

Auto

Automobiles

Auto Directory

Auto Finance

Auto Insurance

Auto Leasing

Auto Auctions

Hybrids (HEV)

Biology

Human Genome Project

Business

Franchises

Business Transportation
Directory

Presidential Address:
Women's Small Business 
Owners

Jobs & Growth Act 2003

Investment Capital

Loan Request Documentation

Merchant Account Comparison

Cell Phones

Cell Phone Info

Computer

Broadband

Data Centers

E-Commerce Tips

Computers & Energy Star

Computer Shopping Page

Wifi Wireless Fidelity

Free Wifi

Consumer News Articles

Consumer News Articles

Forklift Batteries

Clean Energy Systems

Cosmetic Surgery and Financing

CD Manufacturing Services

Organic Baby Furniture

LASIK Procedures and Costs

Culture

Hispanic Heritage Month

Customer Service
Profiles

Digital Photography

Digital Photography Directory

Disabilities

National Disability Employment 
Awareness Month

New Freedom Initiative

FAQ's Disabilities and Work

Workforce Investment Act

Disaster Help

Guide to help
Rebuild Your Home

DVD's

Guide to DVD's

Earthquakes

Preparation, Survival

Electronics

HDTV

Employment

Interviewing

Accountants & Analysts

Administrative Service Managers

Budget Analysts

Construction Managers

Cost Estimators

Employment Interviewers

Engineering, Science, Computer
Systems Managers

Financial Managers

Job Training Initiative

Purchasers / Buyers

Education

Graduate Degrees

Distance Learning

Types of Colleges

Educational Software
Distributors

Original Educational
Software
Initiative by
President Bill Clinton

Energy

Biomass

Buying Clean Electricity

Energy Star

Geothermal

Hydrogen Fuel Cells

Hydropower

Solar

Wind Power

Zero Energy Buildings

Energy Star Technology

Energy Star Homes
FAQ's

Presidential Energy Address
April 2005

Computer Buyers Guide

Energy Star

Spectrally Selective
Low-E Glass

Fashion

Women's Clothing

Financial

Accept Credit Cards

Actividades Bancarias

Bankcruptcy

Capital Access
Grants, Loans

Check 21

Check 21 FAQ

Consumer Credit

Credit Cards

Currency & Coins

Currency: Buying, Selling
Redeeming

E-Commerce Associations
Directory

Electronic Banking

FDIC Insurance

Fair and Accurate Credit
Transaction Act of 2003

Forex Brokerages Directory:

Merchant Accounts

Merchant Account Services
Costs and Fees

Money & Credit Cards

Payment Processing

Stock Market Basics

Fishing

Fishing Guide

Government Info

Government Grant Info

Global Warming Facts

Homeland Security

Preparing America

U.S. Immigration and Visas   

Health

Hospital Comparison

FDA News Digest 
Dec. 03
Contaminated food warnings;
New Drug Treatments ... more

Health Insurance
HIPPA
Government Health Guides

Bird Flu News

What is Influenza? (Flu)

Vioxx

FDA on Vioxx

FDA Vioxx - Press Release

FDA Q & A Vioxx

Identity Theft

Consumer Confidential: 
The Privacy Story

New Law Signed
By President Bush

Information

Information Bank

Insurance

Life Insurance

Long Term Care
 

Jets: Private

Business Aircraft

Cessna

Eclipse 500

Lear

Jewelry

Jewelry Guide

Precious Stones

Legal Guides

Legal Resources

Legal News

Stevens-Johnson
Syndrome

Machinery

Farm, Food Processing
Packaging

Medicare

Medicare Premiums 2004

The Medicare Prescription 
Drug Improvement and 
Modernization Act of 2003

New Medicare Law - FAQ's

Patents & Trademarks

Patents, Trademarks, Copyrights

Press Releases
For Immediate Release

Politics

Political News

Barack Obama

Real Estate

100 Q & A's of
Home Buying

American Dream 
Downpayment Act 

Pardee Homes

Fair Housing Quiz
(HUD)

Financing Energy
Efficient Homes

Home Buying

Home Buying FAQ

Home Buying
Glossary

Home Buying Loans

Home Mortgage
Insurance

Manufactured Homes

Mortgage Refinance

Selling Your Home

Ten Tips For Home Buyers

Real Estate Directories

Sustainable Design:
Energy Efficient Homes

Soccer

Soccer.com
Free Soccer Posters
Shopping

Specialty Directories

Offshore Directories

Real Estate Directories

Featured Directories

Taxes

Tax Tips

Bush Tax Cut

Technology

Data Centers

Megosearch

Nanotechnology


Time

Correct Time

Toxicology

Asbestos Issues

Legislative 

Sen. Bill Frist 

Sen. Hatch

Sen. Murray

Analysis - 
Asbestos Information Act of 1988
H.R. 5442

Benzene

Travel

Tips For Women
Traveling Alone

U.S. Immigration and Visas

State Department Travel Tips

Other Online Guides

e-Commerce

Shopping  

________
Disclaimer

Contact

 

 

Vioxx

FDA Press Release

FOR IMMEDIATE RELEASE
P04-95
September 30, 2004

Media Inquiries: 301-827-6242
Consumer Inquiries: 888-INFO-FDA


FDA Issues Public Health Advisory on Vioxx as its Manufacturer Voluntarily Withdraws the Product

The Food and Drug Administration (FDA) today acknowledged the voluntary withdrawal from the market of Vioxx (chemical name rofecoxib), a non-steroidal anti-inflammatory drug (NSAID) manufactured by Merck & Co. FDA today also issued a Public Health Advisory to inform patients of this action and to advise them to consult with a physician about alternative medications.

Merck is withdrawing Vioxx from the market after the data safety monitoring board overseeing a long-term study of the drug recommended that the study be halted because of an increased risk of serious cardiovascular events, including heart attacks and strokes, among study patients taking Vioxx compared to patients receiving placebo. The study was being done in patients at risk of developing recurrent colon polyps.

"Merck did the right thing by promptly reporting these findings to FDA and voluntarily withdrawing the product from the market," said Acting FDA Commissioner Dr. Lester M. Crawford. "Although the risk that an individual patient would have a heart attack or stroke related to Vioxx is very small, the study that was halted suggests that, overall, patients taking the drug chronically face twice the risk of a heart attack compared to patients receiving a placebo."

Dr. Crawford added that FDA will closely monitor other drugs in this class for similar side effects. "All of the NSAID drugs have risks when taken chronically, especially of gastrointestinal bleeding, but also liver and kidney toxicity. They should only be used continuously under the supervision of a physician."

FDA approved Vioxx in 1999 for the reduction of pain and inflammation caused by osteoarthritis, as well as for acute pain in adults and for the treatment of menstrual pain. It was the second of a new kind of NSAID (Cox-2 selective) approved by FDA. Subsequently, FDA approved Vioxx to treat the signs and symptoms of rheumatoid arthritis in adults and children.

At the time that Vioxx and other Cox-2 selective NSAIDs were approved, it was hoped that they would have a lower risk of gastrointestinal ulcers and bleeding than other NSAIDs (such as ibuprofen and naproxen). Vioxx is the only NSAID demonstrated to have a lower rate of these side effects.

Merck contacted FDA on September 27, 2004, to request a meeting and to advise the agency that the long-term study of Vioxx in patients at increased risk of colon polyps had been halted. Merck and FDA officials met the next day, September 28, and during that meeting the company informed FDA of its decision to remove Vioxx from the market voluntarily.

In June 2000, Merck submitted to FDA a safety study called VIGOR (Vioxx Gastrointestinal Outcomes Research) that found an increased risk of serious cardiovascular events, including heart attacks and strokes, in patients taking Vioxx compared to patients taking naproxen. After reviewing the results of the VIGOR study and other available data from controlled clinical trials, FDA consulted with its Arthritis Advisory Committee in February 2001 regarding the clinical interpretation of this new safety information. In April 2002, FDA implemented labeling changes to reflect the findings from the VIGOR study. The labeling changes included information about the increase in risk of cardiovascular events, including heart attack and stroke.

Recently other studies in patients taking Vioxx have also suggested an increased risk of cardiovascular events. FDA was in the process of carefully reviewing these results, to determine whether further labeling changes were warranted, when Merck informed the agency of the results of the new trial and its decision to withdraw Vioxx from the market.

Additional information about this withdrawal of Vioxx, as well as questions and answers for patients, is available online at http://www.fda.gov/cder/drug
/infopage/vioxx/default.htm
.

Press Releases

Kangaroo Auctions

Flexible Printed Circuits

Proposed Reforms of Tax Exempt Organizations

Government Management Reform

Vioxx

Business Buy and Sell

Submit a Press Release   We only require a reciprocal link.  Please indicate in press release submission the URL where our link will be placed. 
Please use the following: "Consumer Guides: Resources and Information from Around the Nation."

Consumer Tip: Press Releases can be a form of advertising and their truth
claims should be tested as with any advertising or information source.

 

 

Google

 

Web www.consumer-guides.info

 

Vote:
There's a lot at stake...

 

 

 

 

 

2001-2008 Consumer-Guides.Info
Contact